After spending 10 years in contract research, responsible for metabolism and pharmacokinetic studies for regulatory submission by major international companies, David studied for his PhD at Manchester (with Pr. Brian Houston) and subsequently became a Research Fellow within the Centre for Applied Pharmacokinetic Research.
This research is part of the remit of the Centre for Applied Pharmacokinetic Research, within the School, which involves a consortium of five major pharmaceutical companies. Internal collaboration is primarily with Professor Brian Houston.
Royal Society of Chemistry
Royal Society of Biology
International Society for the Study of Xenobiotics
David is responsible for the analytical chemistry facility within the Centre for Applied Pharmacokinetic Research, which provides capability for drug quantitation by liquid chromatography-mass spectrometry for experimental researchers (with three triple-quadrupole intruments).
Prediction of drug metabolic clearance is a cornerstone of successful drug discovery and development. The predictive system framework comprises an in vitro component (human liver cells or isolated enzymes) and an extrapolation model (In vitro-in vivo) component. A generic system, capable of reliable quantitative prediction, remains an important goal and will depend on continued development of all aspects of the system.
Mechanistic principles are key to this development and interest has focussed on drug kinetics in vitro - particularly the critical role of nonspecific binding of drugs and the uptake of drugs into hepatocytes - and the incorporation of these complexities into prediction models.
Current research focusses on understanding the sources of variability (human and experimental) which complicate the use and evaluation of predictive systems.